Arrayit, a California-based company which discovers, develops and manufactures proprietary life science technologies and consumables for disease prevention, treatment and cure, has launched OvaDx, a pre-symptomatic screening test for ovarian cancer.

OvaDx is a microarray-based blood test that measures the activation of the immune system in response to early stage ovarian tumor cell development.

Research studies with OvaDx indicate high sensitivity and specificity for all types and stages of ovarian cancer including stage IA-IV borderline serous, clear cell, endometrioid, mixed epithelial, mucinous, serous, and ovarian adenocarcinoma.

Arrayit said OvaDx is being offered at $650 per test for research purposes only to advance the forefront of ovarian cancer research.